Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Website: vervetx.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.03 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -4.6% (LTM)

Entry Point: Share price is 274.7% higher than minimum and 48.9% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: VERV
Share price, USD:  (0.0%)11.13
year average price 9.18  


year start price 7.71 2025-02-13

min close price 2.97 2025-04-08

max close price 11.38 2025-06-17

current price 11.13 2026-02-12
Common stocks: 17 739 487

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 197
Net Debt ($m): -90
EV (Enterprise Value): 107
Price to Book: 0.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-06-17zacks.com

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly

2025-06-17schaeffersresearch.com

Biotech Stock Surging on Billion-Dollar Buyout

2025-06-17prnewswire.com

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

2025-05-14zacks.com

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates

2025-04-18fool.com

Why Verve Therapeutics Zoomed 40% Higher This Week

2025-04-15zacks.com

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study

2025-01-31prnewswire.com

Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm

2025-01-23zacks.com

Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last?

2025-01-19accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Shareholders to Inquire about Securities Investigation

2024-12-13accesswire.com

VERV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Verve Therapeutics, Inc. and Encourages Investors to Contact the Firm
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VERV VERV VERV VERV VERV VERV VERV VERV VERV VERV VERV VERV VERV
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-05-14 2024-11-05 2024-08-08 2024-05-08 2023-11-07 2023-08-10 2023-05-15 2022-11-07
acceptedDate 2025-05-14 07:30:21 2025-02-27 07:45:29 2024-11-05 07:30:23 2024-08-08 07:30:24 2024-05-08 07:30:33 2024-02-27 08:00:41 2023-11-07 07:30:31 2023-08-10 07:30:56 2023-05-15 07:33:51 2023-03-02 07:31:06 2022-11-07 07:33:07 2022-03-14 07:04:20 2020-12-31 00:00:00
calendarYear 2025 2024 2024 2024 2023 2023 2023 2022
period Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 33M 32M 7M 7M 6M 12M 3M 2M 1M 2M 929 000 0 0
costOfRevenue 0 0 2M 2M 2M 0 3M 3M 0 0 0 3M 1M
grossProfit 33M 32M 5M 5M 4M 12M -82 000 -933 000 1M 2M 929 000 -3M -1M
grossProfitRatio 1 0.745 0.751 0.713 -0.026 -0.446 1 1
researchAndDevelopmentExpenses 54M 204M 50M 51M 48M 185M 44M 47M 47M 130M 35M 68M 35M
generalAndAdministrativeExpenses 15M 57M 14M 15M 14M 50M 12M 13M 13M 38M 10M 19M 5M
sellingAndMarketingExpenses 0 0 0 -2M -2M 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 15M 57M 14M 13M 13M 50M 12M 13M 13M 38M 10M 19M 5M
otherExpenses 0 0 0 2M 78 000 0 802 000 -662 000 738 000 1M 0 -33M -5M
operatingExpenses 70M 261M 64M 64M 61M 235M 55M 61M 60M 168M 45M 87M 41M
costAndExpenses 70M 261M 64M 66M 63M 235M 55M 61M 60M 168M 45M 87M 41M
interestIncome 5M 29M 7M 7M 8M 23M 6M 5M 6M 7M 2M 142 000 162 000
interestExpense 0 0 0 0 0 0 0 0 -6M 0 2M 0 0
depreciationAndAmortization 2M 7M 2M 2M 2M 5M 1M 1M 1M 7M 0 3M 1M
ebitda -35M -222M -55M -57M -55M -218M -52M -57M -58M -163M -44M -86M -39M
ebitdaratio -1.059 -8.034 -8.543 -9.695 -16.79 -27.351 -41.495 -47.212
operatingIncome -37M -229M -57M -59M -57M -223M -52M -59M -58M -166M -44M -87M -41M
operatingIncomeRatio -1.111 -8.29 -8.792 -9.981 -16.79 -27.99 -41.495 -47.212
totalOtherIncomeExpensesNet 6M 30M 7M 9M 8M 23M 7M -662 000 6M 8M -1M -33M -5M
incomeBeforeTax -31M -198M -50M -50M -49M -200M -46M -54M -52M -157M -45M -120M -46M
incomeBeforeTaxRatio -0.939 -7.288 -7.433 -8.539 -14.659 -25.708 -37.019 -48.644
incomeTaxExpense 79 000 349 000 104 000 66 000 106 000 275 000 -67 000 176 000 -6M 53 000 1M 0 0
netIncome -31M -199M -50M -50M -49M -200M -46M -54M -46M -157M -47M -119M -46M
netIncomeRatio -0.941 -7.303 -7.442 -8.558 -14.68 -25.792 -32.543 -50.075
eps -0.35 -2.36 -0.6 -0.59 -0.59 -3.12 -0.72 -0.87 -0.74 -2.91 -0.81 -2.45 -0.94
epsdiluted -0.35 -0.59 -0.59 -0.59 -0.72 -0.87 -0.74 -0.81
weightedAverageShsOut 89M 85M 84M 84M 83M 64M 63M 62M 62M 54M 57M 49M 48M
weightedAverageShsOutDil 89M 85M 85M 84M 83M 64M 63M 62M 62M 54M 57M 49M 48M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-27 2023-03-02 2022-03-14 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 29M 23M 7M 142 000 162 000
ebit -229M -223M -166M -120M -41M
nonOperatingIncomeExcludingInterest 0 0 0 33M 0
netIncomeFromContinuingOperations -199M -200M -157M -120M -46M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -199M -200M -157M -120M -46M
epsDiluted -2.35 -3.12 -2.91 -2.45 -0.94

Balance Sheet Statement

Property 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VERV VERV VERV VERV VERV VERV VERV VERV VERV VERV VERV VERV VERV
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-05-14 2024-11-05 2024-08-08 2024-05-08 2023-11-07 2023-08-10 2023-05-15 2022-11-07
acceptedDate 2025-05-14 07:30:21 2025-02-27 07:45:29 2024-11-05 07:30:23 2024-08-08 07:30:24 2024-05-08 07:30:33 2024-02-27 08:00:41 2023-11-07 07:30:31 2023-08-10 07:30:56 2023-05-15 07:33:51 2023-03-02 07:31:06 2022-11-07 07:33:07 2022-03-14 07:04:20 2020-12-31 00:00:00
calendarYear 2025 2024 2024 2024 2023 2023 2023 2022
period Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 97M 173M 159M 141M 144M 206M 78M 70M 509M 115M 551M 64M 9M
shortTermInvestments 401M 352M 381M 434M 462M 418M 407M 392M 425M 439M 274M 296M 63M
cashAndShortTermInvestments 497M 524M 540M 576M 606M 624M 485M 462M 509M 555M 551M 360M 72M
netReceivables 1M 3M 3M 3M 6M 6M 3M 2M 1M 1M 929 000 0 0
inventory 0 0 0 0 0 0 0 1 -9M 0 0 0 0
otherCurrentAssets 13M 15M 14M 12M 8M 8M 10M 8M 8M 7M 10M 7M 0
totalCurrentAssets 512M 543M 556M 591M 620M 638M 498M 473M 509M 563M 562M 367M 74M
propertyPlantEquipmentNet 95M 97M 100M 102M 105M 108M 108M 110M 111M 111M 106M 9M 4M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 5M 5M 0 5M 5M 0 5M 0 5M 463 000
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 8M 8M 8M 3M 3M 7M 2M 1M 15M 585 000 5M 3M 0
totalNonCurrentAssets 103M 105M 107M 110M 112M 115M 114M 116M 126M 116M 112M 17M 4M
otherAssets 0 0 0 0 1 0 0 0 0 0 0 0 0
totalAssets 614M 647M 664M 701M 732M 753M 612M 589M 634M 679M 673M 384M 78M
accountPayables 5M 5M 5M 7M 3M 7M 1M 3M 3M 2M 465 000 7M 36 000
shortTermDebt 11M 0 21M 21M 10M 0 10M 10M 11M 12M 9M 2M 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 19M 4M 6M 3M 1M 0 49M 20M 20M 20M 20M -13M 90 000
otherCurrentLiabilities 17M 14M 12M 9M 17M 12M -25M -175 000 -1M -261 000 -365 000 5M 0
totalCurrentLiabilities 52M 43M 43M 40M 31M 37M 35M 33M 34M 35M 29M 22M 7M
longTermDebt 58M 0 61M 62M 63M 0 67M 68M 69M 0 71M 0 125M
deferredRevenueNonCurrent 30M 50M 51M 51M 52M 49M 49M 20M 20M 20M 20M 0 125 000
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 1M 1M 1M 1M 3M 3M 2M 3M 2M 3M 67M 5M 10M
totalNonCurrentLiabilities 89M 111M 113M 114M 118M 116M 117M 91M 91M 93M 96M 5M 135M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 69M 70M 71M 72M 63M 75M 77M 78M 80M 82M 80M 2M 0
totalLiabilities 141M 154M 155M 155M 149M 153M 152M 124M 125M 128M 125M 27M 142M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 125M
commonStock 89 000 89 000 85 000 85 000 84 000 82 000 64 000 62 000 62 000 62 000 61 000 49 000 3000
retainedEarnings -774M -743M -693M -643M -593M -544M -496M -450M -396M -344M -303M -187M -67M
accumulatedOtherComprehensiveIncomeLoss 393 000 428 000 1M -615 000 -500 000 272 000 -597 000 -754 000 -237 000 -694 000 -920 000 -228 000 8000
othertotalStockholdersEquity 1 247M 1 200M 1 189M 1 177M 957M 916M 906M 852M
totalStockholdersEquity 474M 493M 509M 546M 583M 600M 460M 465M 509M 551M 548M 357M -64M
totalEquity 474M 493M 509M 546M 583M 600M 460M 465M 509M 551M 548M 357M -64M
totalLiabilitiesAndStockholdersEquity 614M 664M 701M 732M 612M 589M 634M 673M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 614M 647M 664M 701M 732M 753M 612M 589M 634M 679M 673M 384M 78M
totalInvestments 401M 352M 381M 439M 467M 418M 407M 392M 425M 444M 274M 301M 64M
totalDebt 69M 70M 71M 72M 74M 75M 77M 78M 80M 82M 80M 2M 125M
netDebt -28M -103M -87M -69M -71M -131M -2M 8M -429M -33M -471M -62M 116M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-27 2023-03-02 2022-03-14 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 0 0 0 0 0
otherReceivables 3M 6M 1M 0 0
prepaids 0 0 0 0 2M
totalPayables 5M 7M 2M 7M 36 000
otherPayables 0 0 0 0 0
accruedExpenses 10M 8M 9M 6M 7M
capitalLeaseObligationsCurrent 10M 10M 12M 2M 0
capitalLeaseObligationsNonCurrent 60M 65M 70M 0 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 236M 1 143M 896M 544M 3M
otherTotalStockholdersEquity 0 0 0 0 21 000

Cash Flow Statement

Property 2025 q1 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VERV VERV VERV VERV VERV VERV VERV VERV VERV VERV VERV VERV VERV
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-05-14 2024-11-05 2024-08-08 2024-05-08 2023-11-07 2023-08-10 2023-05-15 2022-11-07
acceptedDate 2025-05-14 07:30:21 2025-02-27 07:45:29 2024-11-05 07:30:23 2024-08-08 07:30:24 2024-05-08 07:30:33 2024-02-27 08:00:41 2023-11-07 07:30:31 2023-08-10 07:30:56 2023-05-15 07:33:51 2023-03-02 07:31:06 2022-11-07 07:33:07 2022-03-14 07:04:20 2020-12-31 00:00:00
calendarYear 2025 2024 2024 2024 2023 2023 2023 2022
period Q1 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -31M -199M -50M -50M -49M -200M -46M -54M -52M -157M -45M -120M -46M
depreciationAndAmortization 2M 7M 2M 2M 2M 5M 1M 1M 1M 3M 717 000 2M 1M
deferredIncomeTax 0 0 0 0 0 0 -3M -4M 0 0 0 2M 380 000
stockBasedCompensation 11M 43M 11M 12M 10M 35M 9M 9M 8M 22M 6M 7M 850 000
changeInWorkingCapital -9M -2M -1M 6M -4M 18M 26M -3M -3M 8M 5M -3M 3M
accountsReceivables 2M 3M 410 000 3M 168 000 -6M 0 0 0 -1M 0 0 0
inventory 0 0 0 0 0 0 0 0 0 1M 0 0 0
accountsPayables 729 000 -2M -3M 4M -3M 4M -2M -14 000 1M -5M -5M 7M -2M
otherWorkingCapital -12M -3M 1M -487 999 -904 000 20M 28M -3M -1M 14M 10M -10M 5M
otherNonCashItems -251 000 -7M -924 000 5M 14M -8M 923 000 2M -3M 1M 4M 35M 5M
netCashProvidedByOperatingActivities -28M -158M -40M -34M -43M -150M -12M -48M -49M -122M -29M -78M -35M
investmentsInPropertyPlantAndEquipment -1M -4M -936 000 -980 000 -433 000 -9M -1M -3M -3M -13M -3M -4M -3M
acquisitionsNet 0 0 0 0 0 0 11M -36M 0 143M 0 235M 48M
purchasesOfInvestments -145M -424M -75M -112M -164M -517M -148M -113M -134M -479M -148M -371M -98M
salesMaturitiesOfInvestments 98M 503M 133M 143M 123M 554M 137M 149M 153M 337M 95M 137M 51M
otherInvestingActivites 0 0 31M -41M -11M 36M 0 0
netCashUsedForInvestingActivites -48M 57M 30M -42M -12M 33M 15M -56M
debtRepayment 0 0 0 0 0 0 0 0
commonStockIssued 0 -2M -51 000 23M 32M -65 000 2M 288M
commonStockRepurchased 0 0 472 000 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0
otherFinancingActivites 7000 14 000 1M -51 000 148 000 1M 51 000 503 000
netCashUsedProvidedByFinancingActivities 7000 14 000 1M 23M 32M 1M 2M 288M
effectOfForexChangesOnCash 0 0 0 0 0 0 -3M 18M 0 0 0 0 0
netChangeInCash -76M -34M 22M -3M -62M 91M 8M -14M -32M 51M 204M 60M 6M
cashAtEndOfPeriod 101M 177M 163M 141M 144M 211M 83M 75M 89M 120M 282M 70M 9M
cashAtBeginningOfPeriod 177M 211M 141M 144M 206M 120M 75M 89M 120M 70M 78M 9M 3M
operatingCashFlow -28M -158M -40M -34M -43M -150M -12M -48M -49M -122M -29M -78M -35M
capitalExpenditure -1M -4M -936 000 -980 000 -433 000 -9M -1M -3M -3M -13M -3M -4M -3M
freeCashFlow -29M -161M -41M -35M -44M -159M -13M -51M -52M -136M -32M -82M -39M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-27 2023-03-02 2022-03-14 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 -143M -235M -48M
netCashProvidedByInvestingActivities 75M 28M -156M -239M -51M
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 47M 210M 326M 379M 93M
netCommonStockIssuance 47M 210M 326M 285M 0
commonStockIssuance 47M 210M 326M 285M 93M
netPreferredStockIssuance 0 0 0 94M 93M
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 2M 2M 2M -2M 11 000
netCashProvidedByFinancingActivities 49M 213M 329M 377M 93M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

SEC forms

Show financial reports only

SEC form 8
2025-06-17 11:18 ET
Verve Therapeutics, Inc. published news for 2025 q1
SEC form 8
2025-06-17 11:18 ET
Verve Therapeutics, Inc. published news for 2025 q1
SEC form 8
2025-06-17 11:18 ET
Verve Therapeutics, Inc. published news for 2025 q1
SEC form 8
2025-06-17 11:18 ET
Verve Therapeutics, Inc. published news for 2025 q1
SEC form 8
2025-06-17 11:18 ET
Verve Therapeutics, Inc. published news for 2025 q1
SEC form 8
2025-06-17 11:18 ET
Verve Therapeutics, Inc. published news for 2025 q1
SEC form 10
2025-05-14 11:30 ET
Verve Therapeutics, Inc. reported for 2025 q1
SEC form 8
2025-05-14 11:15 ET
Verve Therapeutics, Inc. reported for 2025 q1
SEC form 8
2025-05-14 11:15 ET
Verve Therapeutics, Inc. published news for 2025 q1
SEC form 10
2025-05-14 00:00 ET
Verve Therapeutics, Inc. reported for 2025 q1
SEC form 10
2025-02-27 12:45 ET
Verve Therapeutics, Inc. reported for 2024 q4
SEC form 8
2025-02-27 00:00 ET
Verve Therapeutics, Inc. reported for 2024 q4
SEC form 8
2025-02-27 00:00 ET
Verve Therapeutics, Inc. published news for 2024 q4
SEC form 10
2025-02-27 00:00 ET
Verve Therapeutics, Inc. reported for 2024 q4
SEC form 10
2024-11-05 07:30 ET
Verve Therapeutics, Inc. reported for 2024 q3
SEC form 8
2024-11-05 07:15 ET
Verve Therapeutics, Inc. published news for 2024 q3
SEC form 8
2024-11-05 07:15 ET
Verve Therapeutics, Inc. reported for 2024 q3
SEC form 10
2024-08-08 07:30 ET
Verve Therapeutics, Inc. reported for 2024 q2
SEC form 8
2024-08-08 07:15 ET
Verve Therapeutics, Inc. reported for 2024 q2
SEC form 8
2024-08-08 07:15 ET
Verve Therapeutics, Inc. published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Verve Therapeutics, Inc. reported for 2024 q2
SEC form 10
2024-05-08 07:30 ET
Verve Therapeutics, Inc. reported for 2024 q1
SEC form 8
2024-05-08 07:15 ET
Verve Therapeutics, Inc. reported for 2024 q1
SEC form 8
2024-05-08 07:15 ET
Verve Therapeutics, Inc. published news for 2024 q1
SEC form 10
2024-05-08 00:00 ET
Verve Therapeutics, Inc. reported for 2024 q1
SEC form 10
2024-02-27 08:00 ET
Verve Therapeutics, Inc. reported for 2023 q4
SEC form 10
2024-02-27 00:00 ET
Verve Therapeutics, Inc. reported for 2023 q4
SEC form 8
2024-02-27 00:00 ET
Verve Therapeutics, Inc. reported for 2023 q4
SEC form 8
2024-02-27 00:00 ET
Verve Therapeutics, Inc. published news for 2023 q4
SEC form 10
2023-11-07 07:30 ET
Verve Therapeutics, Inc. reported for 2023 q3
SEC form 8
2023-11-07 07:00 ET
Verve Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Verve Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-08-10 07:30 ET
Verve Therapeutics, Inc. reported for 2023 q2
SEC form 6
2023-08-10 07:00 ET
Verve Therapeutics, Inc. reported for 2023 q2
SEC form 8
2023-08-10 00:00 ET
Verve Therapeutics, Inc. reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Verve Therapeutics, Inc. reported for 2023 q2
SEC form 6
2023-06-16 09:02 ET
Verve Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-06-15 06:37 ET
Verve Therapeutics, Inc. published news for 2023 q1
SEC form 10
2023-05-15 07:33 ET
Verve Therapeutics, Inc. reported for 2023 q1
SEC form 6
2023-05-15 07:00 ET
Verve Therapeutics, Inc. reported for 2023 q1
SEC form 8
2023-05-15 00:00 ET
Verve Therapeutics, Inc. reported for 2023 q1
SEC form 10
2023-05-15 00:00 ET
Verve Therapeutics, Inc. reported for 2023 q1
SEC form 6
2023-04-28 07:30 ET
Verve Therapeutics, Inc. published news for 2023 q1
SEC form 10
2023-03-02 07:31 ET
Verve Therapeutics, Inc. reported for 2022 q4
SEC form 6
2023-03-02 07:01 ET
Verve Therapeutics, Inc. reported for 2022 q4
SEC form 10
2023-03-02 00:00 ET
Verve Therapeutics, Inc. reported for 2022 q4
SEC form 8
2023-03-02 00:00 ET
Verve Therapeutics, Inc. reported for 2022 q4
SEC form 6
2023-02-17 06:31 ET
Verve Therapeutics, Inc. published news for 2022 q4
SEC form 6
2022-12-05 06:47 ET
Verve Therapeutics, Inc. published news for 2022 q3
SEC form 10
2022-11-07 07:33 ET
Verve Therapeutics, Inc. reported for 2022 q3
SEC form 6
2022-11-07 07:00 ET
Verve Therapeutics, Inc. reported for 2022 q3
SEC form 8
2022-11-07 00:00 ET
Verve Therapeutics, Inc. reported for 2022 q3
SEC form 10
2022-11-07 00:00 ET
Verve Therapeutics, Inc. reported for 2022 q3
SEC form 6
2022-11-02 16:25 ET
Verve Therapeutics, Inc. published news for 2022 q3
SEC form 10
2022-08-09 07:01 ET
Verve Therapeutics, Inc. reported for 2022 q2
SEC form 6
2022-08-09 06:45 ET
Verve Therapeutics, Inc. reported for 2022 q2
SEC form 8
2022-08-09 00:00 ET
Verve Therapeutics, Inc. reported for 2022 q2
SEC form 10
2022-08-09 00:00 ET
Verve Therapeutics, Inc. reported for 2022 q2
SEC form 6
2022-07-21 16:46 ET
Verve Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-07-21 07:01 ET
Verve Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-07-20 16:08 ET
Verve Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-07-12 07:00 ET
Verve Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-07-07 07:06 ET
Verve Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-06-13 16:34 ET
Verve Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-10 07:01 ET
Verve Therapeutics, Inc. reported for 2022 q1
SEC form 6
2022-05-10 06:48 ET
Verve Therapeutics, Inc. published news for 2022 q1
SEC form 8
2022-05-10 00:00 ET
Verve Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Verve Therapeutics, Inc. reported for 2022 q1
SEC form 6
2022-04-29 07:01 ET
Verve Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-03-14 07:04 ET
Verve Therapeutics, Inc. published news for 2021 q4
SEC form 6
2022-03-14 06:49 ET
Verve Therapeutics, Inc. published news for 2021 q4
SEC form 8
2022-03-14 00:00 ET
Verve Therapeutics, Inc. published news for 2021 q4
SEC form 10
2022-03-14 00:00 ET
Verve Therapeutics, Inc. published news for 2021 q4
SEC form 6
2021-11-30 16:25 ET
Verve Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-11-29 17:09 ET
Verve Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-10 07:03 ET
Verve Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-11-10 06:56 ET
Verve Therapeutics, Inc. published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
Verve Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Verve Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-08-24 16:15 ET
Verve Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-08-16 08:01 ET
Verve Therapeutics, Inc. published news for 2021 q2
SEC form 10
2021-08-12 08:53 ET
Verve Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-08-12 08:20 ET
Verve Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-06-21 17:06 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:42 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:42 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:40 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:40 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:38 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:38 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:37 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:35 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:34 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:33 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:31 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:29 ET
Verve Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 19:23 ET
Verve Therapeutics, Inc. published news for 2021 q1